Researchers report that patients diagnosed with moderate to severe plaque psoriasis who were treated with ixekizumab, an investigational anti-interleukin-17A monoclonal antibody, have maintained a favorable clinical response over a year-long course of treatment.
Researchers compared the effectiveness of biologics approved in Europe for the treatment of plaque psoriasis based on their performance as measured by primary endpoints in clinical trials.
Amgen and AstraZeneca recently announced AMAGINE-2TM, a pivotal, multi-arm Phase 3 clinical trial, met all primary endpoints for brodalumab, an experimental drug designed for moderate to severe plaque psoriasis treatment.
The compound AIN457 (secukinumab) has been granted a unanimous vote of support for approval from the Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration.
Amgen has released positive top-line results from the first of two Phase III studies of ABP 501, its candidate for the treatment of moderate-to-severe plaque psoriasis that is being developed as a biosimilar to adalimumab.
People with more severe cases of psoriasis may be at increased risk of uncontrolled hypertension, according to a study published online Oct. 15 in JAMA Dermatology.